Matthew Ingham
Impact in
- Immunology top 10%
- interferon and immune responses
- Immunotherapy and Immune Responses
- Oncology top 10%
- Cancer-related Molecular Pathways
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Papers in
-
- Sarcoma Diagnosis and Treatment 24
- Oncology 28
- CAR-T cell therapy research 9
- Cancer Immunotherapy and Biomarkers 8
- PARP inhibition in cancer therapy 4
- Co-authors
- Gary K. Schwartz (32 shared papers)Jincheng Wu (1 shared paper)Nancy Lewis (1 shared paper)Thomas Müller (1 shared paper)Thomas W. Dubensky (1 shared paper)F. Stephen Hodi (1 shared paper)Xueying Chen (1 shared paper)Jason J. Luke (1 shared paper)
- Journals
- Journal of Clinical Oncology (26 papers)Clinical Cancer Research (4 papers)JCO Precision Oncology (4 papers)Cancer Research (2 papers)Journal for ImmunoTherapy of Cancer (1 paper)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Matthew Ingham
47 papers receiving 875 citations
Matthew Ingham's Hit Papers
Peers
Comparison fields: 5 of 85
- Immunology 304
- Oncology 295
- Pulmonary and Respiratory Medicine 260
- Cancer Research 101
- Infectious Diseases 85
Countries citing papers authored by Matthew Ingham
This map shows the geographic impact of Matthew Ingham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Ingham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Ingham more than expected).
Fields of papers citing papers by Matthew Ingham
This network shows the impact of papers produced by Matthew Ingham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Ingham. The network helps show where Matthew Ingham may publish in the future.
Co-authors
The 25 scholars most cited alongside Matthew Ingham, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 51 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 276 | |
| 2 | Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas Hit paper breakdown → | 2021 | 275 |
| 3 | 2017 | 63 | |
| 4 | 2020 | 29 | |
| 5 | 2025 | 21 | |
| 6 | 2023 | 21 | |
| 7 | 2021 | 21 | |
| 8 | 2020 | 19 | |
| 9 | 2021 | 15 | |
| 10 | 2022 | 10 | |
| 11 | 2022 | 9 | |
| 12 | 2021 | 9 | |
| 13 | 2015 | 9 | |
| 14 | 2020 | 8 | |
| 15 | 2021 | 8 | |
| 16 | 2022 | 6 | |
| 17 | 2022 | 6 | |
| 18 | 2021 | 6 | |
| 19 | 2020 | 6 | |
| 20 | 2022 | 5 |
About Matthew Ingham
Matthew Ingham is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Pathology and Forensic Medicine and Cancer Research, having authored 51 papers that have together received 888 indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (24 papers), CAR-T cell therapy research (9 papers), Cancer Immunotherapy and Biomarkers (8 papers), Protein Degradation and Inhibitors (6 papers), Ovarian cancer diagnosis and treatment (6 papers), Lymphoma Diagnosis and Treatment (6 papers), Cancer Genomics and Diagnostics (4 papers) and PARP inhibition in cancer therapy (4 papers). The work is most often cited by research in Immunology (304 citations), Oncology (295 citations), Pulmonary and Respiratory Medicine (260 citations), Cancer Research (101 citations) and Infectious Diseases (85 citations). Matthew Ingham has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Gary K. Schwartz, Jincheng Wu, Nancy Lewis, Thomas Müller, Thomas W. Dubensky, F. Stephen Hodi, Xueying Chen, Jason J. Luke, Seth M. Pollack and Funda Meric‐Bernstam. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, JCO Precision Oncology, Cancer Research and Journal for ImmunoTherapy of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.